Peptide CDMO capacity buildout is accelerating, with revenue conversion still unproven

SPPS scale-up, impurity control, crystallization, process modeling, and alternative synthesis routes are shaping manufacturing strategy. Indian CDMOs are preparing for a potential peptide supercycle, but only a small minority reportedly generate peptide revenue; customer qualification, contracted volumes, regulatory inspections, and realized sales are more meaningful than announced capacity.